Trials / Recruiting
RecruitingNCT06592638
A Phase 1 Dose Escalation Study of ZG006 in Patients With Small Cell Lung Cancer
A Phase 1 Dose Escalation Study of the Tolerability, Safety, Efficacy and Pharmacokinetics of ZG006 in Patients With Small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This is a multi-center, open-label, Phase 1 clinical study of ZG006 in the US for the treatment of subjects with small cell lung cancer who have failed or are intolerant to available standard treatment. During the dose escalation stage, a standard "3+3" design will be used to assess the MTD/ recommended dose for the subsequent studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ZG006 | ZG006 will be administered as an intravenous (IV) infusion. |
Timeline
- Start date
- 2025-03-31
- Primary completion
- 2026-12-01
- Completion
- 2027-06-01
- First posted
- 2024-09-19
- Last updated
- 2025-08-06
Locations
6 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06592638. Inclusion in this directory is not an endorsement.